KaydedilenlerDerginizi ekleyin

Dergiler / Nöropsikiyatri Arşivi / 2013 / Cilt: 50 - Sayı: 1

Antidepressant treatment strategies in the perinatal period with a focus on SSRI use

Ömer SAATÇİOĞLU
Nesrin Buket TOMRUK
Sayfa
93–94
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

SAATÇİOĞLU, Ö., TOMRUK, N. B. (2013). Antidepressant treatment strategies in the perinatal period with a focus on SSRI use. Nöropsikiyatri Arşivi, Cilt: 50 - Sayı: 1, 93–94. https://ajindex.com/articles/292589

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Altshuler LL, Hendrick V, Cohen L. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 1998; 59: 29-33. Freeman MP. Antenatal depression: Navigating the treatment dilemmas. Am J Psychiatry 2007; 164:1162-165.
  2. Karla S, Einarson A. Prevalence, Clinical Course, and Management of Depression during Pregnancy. In: Hendrick V. (ed) Current Clinical Practice: Psychiatric Disorders in Pregnancy and the Postpartum: Principles and Treatment. Totowa, NJ: Humana Press; 2006, pp 13-40.
  3. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961-966.
  4. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. National Birth Defects Prevention Study. NEJM 2007; 356:2684- 2692. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First- trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. NEJM 2007; 356: 2675-2683.
  5. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 2006; 22: 571-575.
  6. Malm H, Artama M, Gissler M, Ritvanen A. Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. Obstet Gynecol 2011;118:111-20.
  7. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372-2383.
  8. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160 (2): 173-176.
  9. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population- based linked health data. Arch Gen Psychiatry 2006; 63: 898-906.
  10. Misri S, Oberlander TF, Fairbrother N, Carter D, Ryan D, Kuan AJ, Reebye P. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry 2004; 49: 684-689.
  11. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persisten